Intravenous Rehydration in Malnourished Children: Data vs. Dogma
- What: The FDA approved arexvy, a respiratory syncytial virus (RSV) vaccine, for adults aged 60 years and older.
- When: Approved May 3, 2023, with data published October 2, 2025, in the New England Journal of Medicine.
- why it Matters: RSV causes significant illness and hospitalization in older adults, and this is the first FDA-approved vaccine too prevent it.
RSV Vaccine Approved for Older Adults: A Breakthrough in Respiratory Protection
Table of Contents
Understanding RSV and Why It’s a Threat to Seniors
Respiratory Syncytial Virus (RSV) is a common respiratory virus that usually causes mild,cold-like symptoms. However, for older adults, RSV can led to severe illness, including pneumonia and hospitalization. Before the availability of a vaccine, RSV was estimated to cause approximately 60,000-160,000 hospitalizations and 6,000-10,000 deaths annually among adults 65 years and older in the United states.
The virus spreads through close contact with infected individuals, much like the common cold or flu. Symptoms can include a runny nose, cough, fever, and shortness of breath.Older adults are particularly vulnerable as their immune systems weaken with age, making them less able to fight off the infection effectively.
The Arexvy Vaccine: How it effectively works and Trial Results
Arexvy, developed by GSK, is a recombinant subunit vaccine containing a stabilized prefusion F protein. This protein is found on the surface of the RSV virus and is crucial for the virus to enter cells. By presenting this protein to the immune system, the vaccine prompts the body to create antibodies that can neutralize the virus and prevent infection.
The approval of Arexvy is based on data from the RSVAPEX trial, a large, randomized, placebo-controlled study involving nearly 24,636 adults aged 60 years and older. The trial, detailed in the October 2, 2025, issue of the New England Journal of Medicine, demonstrated that Arexvy was 82.6% effective in preventing RSV-associated lower respiratory tract disease (LRTD) – defined as having at least two symptoms, such as cough, shortness of breath, or wheezing – with a confirmed RSV infection. The vaccine also showed 94.1% efficacy in preventing severe LRTD.
Importantly, the trial also monitored for safety. The moast common side effects reported were pain at the injection site, fatigue, muscle aches, headache, and joint pain. Serious adverse events were rare and not substantially different between the vaccine and placebo groups.
Who Should Get the RSV Vaccine?
The FDA approved Arexvy for adults aged 60 years and older. The Centers for Disease Control and Prevention (CDC) recommends that adults aged 60 years and older may receive a single dose of RSV vaccine, based on shared clinical decision-making with their healthcare provider.
This means that individuals should discuss their risk factors for RSV with their doctor to determine if vaccination is right for them. Factors to consider include age, underlying health conditions (such as heart or lung disease, diabetes, or a weakened immune system), and living situation (such as residing in a nursing home or assisted living facility).
RSV Vaccine vs. Flu and COVID-19 Vaccines: What’s the Difference?
| Vaccine | Target Virus | Recommended Age | Frequency
Keep reading |
|---|